Alpha 2.0
Login Register
» Authors » E Raschi

E Raschi

Explore the profile of E Raschi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 39
Citations 740
Followers 0
Related Specialties
Rheumatology
Allergy & Immunology
Endocrinology
Top 10 Co-Authors
P L Meroni
M O Borghi
A Tincani
C Testoni
F De Ponti
G BALESTRIERI
E Poluzzi
N Del Papa
M A Khamashta
P Panzeri
Published In
Lupus
Nutr Metab Cardiovasc Dis
Arthritis Rheum
Clin Exp Immunol
J Autoimmun
Affiliations
Soon will be listed here.
Recent Articles
1.
Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
Gastaldon C, Arzenton E, Raschi E, Spigset O, Papola D, Ostuzzi G, et al.
Psychol Med . 2022 Sep; 53(12):5645-5653. PMID: 36128628
Background: Evidence on neonatal withdrawal syndrome following antidepressant intrauterine exposure is limited, particularly for antidepressants other than selective serotonin reuptake inhibitor (SSRIs). Methods: In our case/non-case pharmacovigilance study, based on...
2.
The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice
Raschi E, La Placa M, Poluzzi E, De Ponti F
Br J Dermatol . 2020 Nov; 184(3):581-583. PMID: 33184850
No abstract available.
3.
Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction
Raschi E, Salvo F, La Placa M, Poluzzi E, De Ponti F
J Eur Acad Dermatol Venereol . 2020 Mar; 34(8):e430-e431. PMID: 32191362
No abstract available.
4.
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al.
Nutr Metab Cardiovasc Dis . 2018 Apr; 28(6):533-542. PMID: 29625780
Sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) have consistently demonstrated a clinically significant reduction of cardiovascular mortality. However, their safety in clinical practice is still incompletely characterized, and post-marketing monitoring is required considering...
5.
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems
Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, et al.
Nutr Metab Cardiovasc Dis . 2017 Nov; 27(12):1098-1107. PMID: 29174026
Background And Aims: We assessed post-marketing safety of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) by analyzing adverse events (AEs) reported in international pharmacovigilance databases. Methods And Results: Eudravigilance, WHO-Vigibase (as of Feb...
6.
Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit
Girardi A, Galletti S, Raschi E, Koci A, Poluzzi E, Faldella G, et al.
Ital J Pediatr . 2017 Apr; 43(1):37. PMID: 28412957
Background: Drug use in preterm neonates admitted to Neonatal Intensive Care Unit (NICU) has been investigated, so far, in terms of unauthorized or off-label use; very little is known on...
7.
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution
Raschi E, Bianchin M, Poluzzi E, De Ponti F
Neurogastroenterol Motil . 2017 Jan; 29(2). PMID: 28132439
No abstract available.
8.
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
Raschi E, Poluzzi E, Koci A, Antonazzo I, Marchesini G, De Ponti F
Nutr Metab Cardiovasc Dis . 2016 Apr; 26(5):380-6. PMID: 27067162
Background And Aims: We tested the possible association between dipeptidyl peptidase-4 inhibitors (DPP-4-I) use and heart failure (HF) occurrence by assessing the publicly available US-FDA Adverse Event Reporting System (FAERS)....
9.
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies
Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, et al.
Clin Pharmacol Ther . 2015 Aug; 99(3):306-14. PMID: 26272741
To estimate the risk of sudden cardiac death (SCD) or sudden unexpected death (SUD) related to individual antipsychotics, a meta-analysis of observational studies was performed. Adjusted odds ratio (OR) of...
10.
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies
Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, DAlessandro R, et al.
Cephalalgia . 2014 Sep; 35(2):118-31. PMID: 25246519
Background: Apart from the underlying cardiovascular (CV) risk associated with migraine, both triptans and ergotamines can induce vasoconstriction and potentially increase the risk of serious ischemic events. Because of the...